Engineered Heart Muscle Models in Phenotypic Drug Screens

Area of Science:

• Biomedical Engineering
• Stem Cell Biology
• Pharmacology

Background:

• Classical drug development faces high clinical failure rates due to safety and efficacy issues.
• Current preclinical models, including in vitro and animal studies, have limitations in predicting human responses.
• Human pluripotent stem cells offer a pathway to create patient-specific cells for more accurate drug testing.

Purpose of the Study:

• To explore the potential of tissue-engineered human heart muscle models in drug discovery and safety pharmacology.
• To evaluate whether these human models can replace or enhance existing preclinical tools.
• To facilitate the translation of promising drug candidates into clinical practice.

Main Methods:

• Utilizing human pluripotent stem cells directed into specific cardiac cell types.
• Developing macro-scale, tissue-engineered heart muscle constructs.
• Applying these models for drug candidate screening and safety assessment.

Main Results:

• Overview of the development and application of macro-scale engineered heart muscle.
• Discussion on the potential information gain compared to traditional models.
• Exploration of how these models can improve preclinical data packages.

Conclusions:

• Tissue-engineered human heart muscle models represent a significant advancement in preclinical drug evaluation.
• These models hold promise for improving the accuracy of safety and efficacy predictions.
• Further research is needed to fully integrate these human-based systems into the drug development pipeline.